文献速递肿瘤 PET/CT

局部晚期头颈癌双时间点显像评估放化疗后残留淋巴结病变

Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy.
PubMed 文献 · EJNMMI Res · 2022-06-13

本研究为ECLYPS研究的预设计次要终点分析,共纳入102例局部晚期头颈部鳞癌患者,在同步放化疗后12周行FDG-PET/CT双时间点显像(60和120分钟),以组织学、1年FDG-PET/CT阴性或>2年临床随访为参考标准。结果显示双时间点显像未显著提高总体诊断准确性(AUROC比较P=0.62),联合阈值(SUV1≥2.2且RI≥3%)使假阳性减少53%(P=0.02),特异性从80.5%升至90.8%,阳性预测值从37.0%升至52.9%,但敏感性从66.7%降至60.0%。

要点

  • 双时间点FDG-PET/CT未显著改善放化疗后12周残留淋巴结病变的总体诊断准确性(AUROC比较P=0.62)。
  • 联合阈值SUV1≥2.2且RI≥3%使假阳性减少53%(P=0.02),特异性90.8% vs 80.5%,阳性预测值52.9% vs 37.0%。
  • 联合阈值下敏感性60.0% vs 66.7%,阴性预测值92.9% vs 93.3%,保持相近的高水平。

核心结论

  • 双时间点显像未提高同步放化疗后12周FDG-PET/CT检测残留病变的总体诊断准确性。
  • 由于良恶性淋巴结示踪剂动力学差异,双时间点显像提高了特异性,但以敏感性轻度降低为代价。
  • 12周PET/CT假阴性主要源于微小残留病变,双时间点显像无法显著提高敏感性,作者认为 later 复查(如12个月后)可能解决此问题。
  • 作者指出HPV相关疾病需进一步研究。

研究设计与样本

  • ECLYPS研究的预设计次要终点分析,共102例受试者纳入分析。
  • 局部晚期头颈部鳞状细胞癌患者完成同步放化疗后12周行标准化头颈部FDG-PET/CT,分别在示踪剂注射后60和120分钟采集。
  • 对淋巴结行半定量评估,探索滞留指数(RI)以优化诊断性能。
  • 参考标准为组织学、1年FDG-PET/CT阴性或>2年临床随访。
  • 计算时间依赖性受试者工作特征曲线下面积(AUROC)。

主要发现

  • 恶性淋巴结SUV值升高(中位SUV1=2.6 vs SUV2=2.7;P=0.04),良性淋巴结无升高(中位SUV1=1.8 vs SUV2=1.7;P=0.28)。
  • 良性淋巴结RI为负但变异大(中位RI=-2.6;IQR 21.2),恶性淋巴结RI为正(中位RI=12.3;IQR 37.2),恶性淋巴结RI显著高于良性淋巴结(P=0.018)。
  • 联合阈值(SUV1≥2.2且RI≥3%)使假阳性病例减少53%(P=0.02),特异性90.8% vs 80.5%,阳性预测值52.9% vs 37.0%。
  • 联合阈值下敏感性60.0% vs 66.7%,阴性预测值92.9% vs 93.3%,保持相近的高水平。
  • AUROC作为诊断准确性总体获益指标未显著改善(P=0.62)。

关键数值与推荐

  • 联合阈值定义为SUV1≥2.2且RI≥3%。
  • 联合阈值下假阳性减少53%(P=0.02),特异性90.8% vs 80.5%,阳性预测值52.9% vs 37.0%,敏感性60.0% vs 66.7%,阴性预测值92.9% vs 93.3%。
  • 恶性淋巴结中位SUV1=2.6 vs SUV2=2.7(P=0.04);良性淋巴结中位SUV1=1.8 vs SUV2=1.7(P=0.28)。
  • 良性淋巴结中位RI=-2.6(IQR 21.2),恶性淋巴结中位RI=12.3(IQR 37.2),组间比较P=0.018。
  • AUROC比较P=0.62。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • HPV相关疾病亚组样本量小(n=32)。
  • 作者指出HPV相关疾病需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: FDG-PET/CT has a high negative predictive value to detect residual nodal disease in patients with locally advanced squamous cell head and neck cancer after completing concurrent chemoradiotherapy (CCRT). However, the positive predictive value remains suboptimal due to inflammation after radiotherapy, generating unnecessary further investigations and possibly even surgery. We report the results of a preplanned secondary end point of the ECLYPS study regarding the potential advantages of dual time point FDG-PET/CT imaging (DTPI) in this setting. Standardized dedicated head and neck FDG-PET/CT images were obtained 12 weeks after CCRT at 60 and 120 min after tracer administration. We performed a semiquantitative assessment of lymph nodes, and the retention index (RI) was explored to optimize diagnostic performance. The reference standard was histology, negative FDG-PET/CT at 1 year, or > 2 years of clinical follow-up. The time-dependent area under the receiver operator characteristics (AUROC) curves was calculated. RESULTS: In total, 102 subjects were eligible for analysis. SUV values increased in malignant nodes (median SUV1 = 2.6 vs. SUV2 = 2.7; P = 0.04) but not in benign nodes (median SUV1 = 1.8 vs. SUV2 = 1.7; P = 0.28). In benign nodes, RI was negative although highly variable (median RI = - 2.6; IQR 21.2), while in malignant nodes RI was positive (median RI = 12.3; IQR 37.2) and significantly higher (P = 0.018) compared to benign nodes. A combined threshold (SUV1 ≥ 2.2 + RI ≥ 3%) significantly reduced the amount of false-positive cases by 53% (P = 0.02) resulting in an increased specificity (90.8% vs. 80.5%) and PPV (52.9% vs. 37.0%), while sensitivity (60.0% vs. 66.7%) and NPV remained comparably high (92.9% vs. 93.3%). However, AUROC, as overall measure of benefit in diagnostic accuracy, did not significantly improve (P = 0.62). In HPV-related disease (n = 32), there was no significant difference between SUV1, SUV2, and RI in malignant and benign nodes, yet this subgroup was small. CONCLUSIONS: DTPI did not improve the overall diagnostic accuracy of FDG-PET/CT to detect residual disease 12 weeks after chemoradiation. Due to differences in tracer kinetics between malignant and benign nodes, DTPI improved the specificity, but at the expense of a loss in sensitivity, albeit minimal. Since false negatives at the 12 weeks PET/CT are mainly due to minimal residual disease, DTPI is not able to significantly improve sensitivity, but repeat scanning at a later time (e.g. after 12 months) could possibly solve this problem. Further study is required in HPV-associated disease.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Soffers F, Helsen N, Van den Wyngaert T, et al. Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy. EJNMMI Res. 2022. PMID: 35695940. doi:10.1186/s13550-022-00905-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。